|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present meta-analysis, we demonstrated that the homozygous variant genotypes in <i>ERCC2</i> rs1799793 and <i>ERCC5</i> rs2296147 were significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR = 0.62, 95% CI = 0.41-0.93, <i>P</i><sub>heterogeneity</sub> = 0.310, <i>I</i><sup>2</sup> = 15.3%, <i>P</i> = 0.020; TT vs CC for rs2296147: HR = 0.42, 95% CI = 0.23-0.78, <i>P</i><sub>heterogeneity</sub> = 0.708, <i>I</i><sup>2</sup> = 0.0%, <i>P</i> = 0.006).
|
29950854 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.
|
30402838 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Participants rs1799793-GT or -TT and rs4150441-GA or -AA genotype have the highest osteosarcoma risk, compared to subjects with rs1799793-GG and rs4150441-GG genotype, OR (95% CI) = 2.87 (1.21-4.63), after covariates adjustment.
|
28474168 |
2017 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis did not reveal significant associations between ERCC2 rs13181/rs1799793 or ERCC3 rs4150441/ rs4150506 gene polymorphisms and the development of osteosarcoma in codominant, dominant, and recessive models.
|
27051024 |
2016 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our study found that the ERCC2 Asn312Asp gene polymorphism likely plays an important role in influencing the chemotherapy response and overall survival of patients with osteosarcoma.
|
26505449 |
2015 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, there is no evidence of association on ERCC1 Asn118Asn, ERCC1 Gln504Lys, and ERCC2 Asp312Asn polymorphisms with prognosis in osteosarcoma.
|
25023406 |
2014 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study suggests that XPD rs1799793 could be a marker of os</span>teosarcoma associated with features conferring either a better prognosis or a better outcome after platinum therapy, or both.
|
21826087 |
2012 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis did not reveal significant associations between ERCC2 rs13181/rs1799793 or ERCC3 rs4150441/ rs4150506 gene polymorphisms and the development of osteosarcoma in codominant, dominant, and recessive models.
|
27051024 |
2016 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Through quantitative analysis, the meta-analysis showed that ERCC2 Lys751Gln (ORGG vs. AA = 0.40 (95%CI = 0.1-0.86), P heterogeneity = 0.502; I (2) = 0 %) and ERCC5 His46His (ORCC vs. TT = 0.37 (95%CI = 0.15-0.93), P heterogeneity = 0.569; I (2) = 0 %) polymorphisms might influence the prognosis of patients with osteosarcoma [1].
|
25824708 |
2015 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, the ERCC2 Lys751Gln and ERCC5 His46His polymorphisms might influence osteosarcoma prognosis.
|
25023406 |
2014 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our study indicated that GSTP1 and ERCC2 Lys751Gln polymorphisms might be candidate pharmacogenomic factors to be explored in the future to identify osteosarcoma patients who might benefit from chemotherapy.
|
23317281 |
2012 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |
|
rs171140
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs756340448
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |